Key Highlights
- DARE shares traded near $0.72 at last closing, with a market Capitalization in the range of roughly $11 million to $14 million.
- The company received an NIH award worth approximately $908,000 to advance DARE-PTB2 for preterm-birth prevention on August 31, 2026.
- Dare priced a $6.0 million registered direct offering at $1.37 per share on August 14, 2026.
- Its Flora Sync LF5 launch in July 2026 generated the company's first consumer product revenue.
Dare Bioscience, Inc. (NASDAQ:DARE) has quietly turned into one of the more active names in women's health this summer, even as its shares trade below a dollar. The Nasdaq-listed company, ticker DARE, spent August 2026 stacking up developments: a fresh federal research grant, new peer-reviewed data, a capital raise and the early commercial rollout of consumer products. With a strong-buy analyst tag and a slate of milestones on the horizon, the San Diego drug developer has drawn renewed attention despite its small size.
Company and Latest Development
Dare Bioscience develops and commercializes products for women's health, spanning contraception, sexual health, fertility and vaginal health. Its portfolio includes XACIATO, an FDA-approved treatment for bacterial vaginosis licensed to Organon, alongside a pipeline led by Ovaprene, an investigational hormone-free monthly contraceptive, and DARE-HPV. The most recent verified catalyst came on August 31, 2026, when Dare announced a new notice of award from the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development worth approximately $908,000 to advance DARE-PTB2 for preterm-birth prevention, with recommended future-year support of about $1.3 million.
What Is Driving Attention Around DARE?
A cluster of announcements, rather than a single blockbuster event, explains the interest. In July 2026 Dare launched Flora Sync LF5, generating its first consumer revenue, and expanded access to its DARE to PLAY product through a Partnership with telehealth platform MyMenopauseRx. On August 26, 2026 research on its topical sildenafil cream was published in Menopause, and the company reported second-quarter results on August 13. Shortly after, on August 14, Dare priced a $6.0 million registered direct offering at $1.37 per share with concurrent warrants. The modest single-day gain reflected at last closing does not tie to one confirmed catalyst, but the steady news flow has kept the stock in view.
Key Numbers and Company Position
Verified figures include second-quarter 2026 Revenue of about $0.19 million, reflecting the early stage of consumer commercialization. The August offering raised $6.0 million in gross proceeds at $1.37 per share. Recent market data placed the shares near $0.72 with a market capitalization in the range of roughly $11 million to $14 million, keeping Dare a small-cap. The NIH award adds roughly $908,000 in non-dilutive funding for DARE-PTB2. Analysts tracking the stock have maintained a strong-buy stance, though price targets are inherently uncertain.
What Could Come Next?
Dare has pointed to major clinical milestones expected in 2027 for both Ovaprene and DARE-HPV, making progress on those programs central to the outlook. Nearer term, investors may be watching the commercial ramp of Flora Sync and DARE to PLAY, any additional partnership or licensing revenue, and preclinical progress on DARE-PTB2 supported by the NIH grant. Updates on cash runway following the August raise, and any further Royalty flow from XACIATO, are also worth monitoring.
Risks to Watch
As a small-cap developer transitioning toward commercialization, Dare faces meaningful risks. Its shares trade below $1, raising the potential for Nasdaq minimum-bid-price compliance concerns and possible corrective actions. Recurring operating losses and a modest cash position point to likely future financing needs and dilution, as the August offering illustrates. Clinical and Regulatory Risk remains for Ovaprene, DARE-HPV and earlier-stage programs, and early consumer revenue is still very small relative to expenses. Competition in women's health is significant.
A Busy August for a Women's-Health Developer
Dare Bioscience heads into late 2026 with fresh non-dilutive funding, new clinical data, early consumer sales and a pipeline pointing toward 2027 catalysts. Investors may want to monitor the Flora Sync and DARE to PLAY rollouts, progress on Ovaprene and DARE-HPV, and the company's balance sheet.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...